Photodynamic therapy on chronic pathology during the post-COVID19 and worldwide shortage of verteporfin (Visudyne®) era

IF 2.6 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy Pub Date : 2025-07-11 DOI:10.1016/j.pdpdt.2025.104711

Ana Boned-Murillo , Mª Jesús López-Prats Lucea , Enrique Alfonso Muñoz , Lourdes Vidal-Oliver , Jorge Mataix Boronat , Elena Palacios Pozo , Mª Carmen Desco Esteban

{"title":"Photodynamic therapy on chronic pathology during the post-COVID19 and worldwide shortage of verteporfin (Visudyne®) era","authors":"Ana Boned-Murillo , Mª Jesús López-Prats Lucea , Enrique Alfonso Muñoz , Lourdes Vidal-Oliver , Jorge Mataix Boronat , Elena Palacios Pozo , Mª Carmen Desco Esteban","doi":"10.1016/j.pdpdt.2025.104711","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>We analyze COVID19 pandemia and shortage of verteporfin (Visudyne®) consequences in photodynamic therapy (PDT) treated patients.</div></div><div><h3>Material and methods</h3><div>A retrospective study was performed in 97 patients treated with PDT last 3 years. We used HALF DOSE PDT for chronic central serous chorioretinopathy (cCSCR) (<em>n</em> = 84) and FULL DOSE for polypoidal choroidal vasculopathy (PCV) (<em>n</em> = 13). We evaluated changes in visual acuity (VA) and resolution of subretinal fluid (SRF) by optical coherence tomography (OCT), assessing the number of retreatments.</div></div><div><h3>Results</h3><div>The mean referral delay time was 28.5 ± 6.24 months. 53.6 % of cCSCR and 75 % of PCV patients received previous treatments. An improvement in VA was observed in cCSCR patients after treatment, while PCV patients tends to stabilization. Patients with longer therapeutic delay (≥1 year) showed worse VA. Complete resolution of SRF was noted in 71.4 % of cCSCR and 83.3 % of PCV patients. The shorter the referral delay, the better the resolution rate (76.9 % < 1 year vs 61.5 % if ≥1 year). One-third-of patients required retreatment, superior if longer delay (26.9 % if <1 year vs 34.3 % if ≥1 year).</div></div><div><h3>Conclusion</h3><div>Even with referral delay or chronic evolution, PDT is worth it and safe to resolve SRF or polyps activity for cCSCR and PCV.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"55 ","pages":"Article 104711"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photodiagnosis and Photodynamic Therapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1572100025002431","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

We analyze COVID19 pandemia and shortage of verteporfin (Visudyne®) consequences in photodynamic therapy (PDT) treated patients.

Material and methods

A retrospective study was performed in 97 patients treated with PDT last 3 years. We used HALF DOSE PDT for chronic central serous chorioretinopathy (cCSCR) (n = 84) and FULL DOSE for polypoidal choroidal vasculopathy (PCV) (n = 13). We evaluated changes in visual acuity (VA) and resolution of subretinal fluid (SRF) by optical coherence tomography (OCT), assessing the number of retreatments.

Results

The mean referral delay time was 28.5 ± 6.24 months. 53.6 % of cCSCR and 75 % of PCV patients received previous treatments. An improvement in VA was observed in cCSCR patients after treatment, while PCV patients tends to stabilization. Patients with longer therapeutic delay (≥1 year) showed worse VA. Complete resolution of SRF was noted in 71.4 % of cCSCR and 83.3 % of PCV patients. The shorter the referral delay, the better the resolution rate (76.9 % < 1 year vs 61.5 % if ≥1 year). One-third-of patients required retreatment, superior if longer delay (26.9 % if <1 year vs 34.3 % if ≥1 year).

Conclusion

Even with referral delay or chronic evolution, PDT is worth it and safe to resolve SRF or polyps activity for cCSCR and PCV.

查看原文本刊更多论文

后covid - 19和全球维替泊芬（Visudyne®）短缺时代的慢性病理光动力治疗。

背景：我们分析了covid - 19大流行和光动力治疗（PDT）患者中维替泊芬（Visudyne®）短缺的后果。材料与方法：对97例近3年的PDT患者进行回顾性研究。我们使用半剂量PDT治疗慢性中枢性浆液性脉络膜视网膜病变（cCSCR）（n=84）和全剂量治疗息肉样脉络膜血管病变（PCV）（n=13）。我们通过光学相干断层扫描（OCT）评估视力（VA）和视网膜下液（SRF）分辨率的变化，评估再治疗的次数。结果：平均延迟转诊时间28.5±6.24个月。53.6%的cCSCR和75%的PCV患者既往接受过治疗。cCSCR患者治疗后VA有所改善，而PCV患者趋于稳定。治疗延迟较长（≥1年）的患者表现出更差的VA。71.4%的cCSCR患者和83.3%的PCV患者的SRF完全消退。转诊延迟越短，治愈率越好（< 1年为76.9%，≥1年为61.5%）。结论：即使有转诊延迟或慢性进展，PDT对于解决cCSCR和PCV的SRF或息肉活动是值得的，也是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Photodiagnosis and Photodynamic Therapy ONCOLOGY-

CiteScore

5.80

自引率

24.20%

发文量

509

审稿时长

50 days

期刊介绍： Photodiagnosis and Photodynamic Therapy is an international journal for the dissemination of scientific knowledge and clinical developments of Photodiagnosis and Photodynamic Therapy in all medical specialties. The journal publishes original articles, review articles, case presentations, "how-to-do-it" articles, Letters to the Editor, short communications and relevant images with short descriptions. All submitted material is subject to a strict peer-review process.